Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin OTC Actual Use Study
NCT02573311Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2015
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tamsulosin in lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of Men Who Report a Condition Listed Under the 'Stop Use and Ask a Doctor if' Section of the DFL Within the First 12 Weeks of Using Study Product and do Not Stop Use or Initiate Contact… Started Sep 2015; status: completed.
02
Drugs
tamsulosin
03
Conditions
lower urinary tract symptoms (LUTS)benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT02573311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02573311.